ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 267 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is 0.63 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,139,565 | -24.6% | 154,059 | 0.0% | 0.00% | -20.0% |
| Q2 2023 | $5,493,744 | +40.4% | 154,059 | 0.0% | 0.01% | +66.7% |
| Q1 2023 | $3,913,099 | -58.3% | 154,059 | -33.4% | 0.00% | -62.5% |
| Q4 2022 | $9,377,188 | +21.2% | 231,193 | -1.3% | 0.01% | +14.3% |
| Q3 2022 | $7,738,000 | +7.4% | 234,142 | +14.4% | 0.01% | 0.0% |
| Q2 2022 | $7,208,000 | -23.3% | 204,705 | +0.2% | 0.01% | 0.0% |
| Q1 2022 | $9,399,000 | -35.6% | 204,377 | -7.2% | 0.01% | -30.0% |
| Q4 2021 | $14,595,000 | +14.3% | 220,142 | +7.7% | 0.01% | 0.0% |
| Q3 2021 | $12,764,000 | -24.3% | 204,456 | +0.4% | 0.01% | -23.1% |
| Q2 2021 | $16,867,000 | +13.3% | 203,656 | -9.3% | 0.01% | +18.2% |
| Q1 2021 | $14,889,000 | -13.0% | 224,542 | +0.6% | 0.01% | -15.4% |
| Q4 2020 | $17,120,000 | +87.3% | 223,126 | +5.1% | 0.01% | +62.5% |
| Q3 2020 | $9,141,000 | -6.0% | 212,290 | -5.8% | 0.01% | -20.0% |
| Q2 2020 | $9,729,000 | +57.5% | 225,262 | +4.9% | 0.01% | +42.9% |
| Q1 2020 | $6,176,000 | -70.5% | 214,681 | -35.0% | 0.01% | -63.2% |
| Q4 2019 | $20,934,000 | +158.0% | 330,029 | +14.6% | 0.02% | +137.5% |
| Q3 2019 | $8,114,000 | +22.6% | 287,950 | +15.3% | 0.01% | 0.0% |
| Q2 2019 | $6,618,000 | +34.9% | 249,752 | -6.6% | 0.01% | +33.3% |
| Q1 2019 | $4,905,000 | +46.2% | 267,310 | -1.1% | 0.01% | +20.0% |
| Q4 2018 | $3,356,000 | -39.3% | 270,210 | -6.2% | 0.01% | -28.6% |
| Q3 2018 | $5,525,000 | +74.6% | 288,210 | +23.9% | 0.01% | +75.0% |
| Q2 2018 | $3,164,000 | +87.1% | 232,622 | -0.8% | 0.00% | +100.0% |
| Q1 2018 | $1,691,000 | +95.9% | 234,500 | 0.0% | 0.00% | +100.0% |
| Q4 2017 | $863,000 | -15.0% | 234,500 | 0.0% | 0.00% | -50.0% |
| Q3 2017 | $1,015,000 | +167.1% | 234,500 | 0.0% | 0.00% | +100.0% |
| Q2 2017 | $380,000 | -12.4% | 234,500 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $434,000 | +14.5% | 234,500 | -4.1% | 0.00% | 0.0% |
| Q4 2016 | $379,000 | -79.9% | 244,600 | -4.9% | 0.00% | -66.7% |
| Q3 2016 | $1,890,000 | +29.2% | 257,200 | -6.4% | 0.00% | +50.0% |
| Q2 2016 | $1,463,000 | – | 274,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,264 | $54,392,000 | 33.22% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $216,228,000 | 28.00% |
| L1 Capital Pty Ltd | 296,024 | $19,629,000 | 4.93% |
| Aquilo Capital Management, LLC | 407,926 | $27,050,000 | 4.89% |
| Evolutionary Tree Capital Management, LLC | 72,948 | $4,837,000 | 2.86% |
| ACUTA CAPITAL PARTNERS, LLC | 108,000 | $7,161,000 | 2.58% |
| First Light Asset Management, LLC | 536,836 | $35,598,000 | 2.36% |
| Parkman Healthcare Partners LLC | 70,089 | $4,648,000 | 1.08% |
| Hood River Capital Management LLC | 357,082 | $23,678,000 | 0.76% |
| Vanguard Capital Wealth Advisors | 11,099 | $703,565,000 | 0.60% |